Welcome to our dedicated page for BioAge Labs SEC filings (Ticker: BIOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
BioAge Labs, Inc. principal accounting officer Shane Barton exercised stock options and sold shares of common stock in late June. He exercised options covering 59,934 shares at strike prices between $4.30 and $10.85 per share, then sold a total of 62,566 shares in open-market transactions at weighted average prices around $25 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and after these trades he reported holding no shares of common stock directly.
BIOA filed a Form 144 reporting proposed sale activity related to a stock option exercise. The filing lists a planned sale tied to a stock option exercise on 06/30/2026 and records 42,350 shares sold on 06/29/2026 for $1,067,577.87. The broker named is Fidelity Brokerage Services LLC.
BIOA submitted a notice under Section 144 relating to proposed sales of Common stock. The excerpt lists transactions dated 09/26/2024 ("IPO Shares", quantity 2,632) and 06/29/2026 ("Stock Option Exercise", quantity 39,718). The filing lists a broker-dealer Fidelity Brokerage Services LLC and shows values including 1,067,577.56 and a figure 44,452,734.
BioAge Labs, Inc. director Vijay Satyanand Pande received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and expire on June 9, 2036, bringing his directly held option position reported here to 22,000 shares. The entire award vests on the earlier of the next annual stockholder meeting or one year from the grant date, if he continues serving the company.
BioAge Labs, Inc. director Rekha Hemrajani received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or one year from the grant date, subject to her continued service. Following this grant, she holds options for 22,000 shares directly.
BioAge Labs, Inc. director James Healy received a grant of stock options tied to the company’s common stock. The award covers 22,000 options with an exercise price of $15.48 per share and expires on June 9, 2036.
According to the terms, the entire option award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, provided Healy continues to serve the company through the applicable vesting date. After this grant, he holds 22,000 derivative securities directly.
BioAge Labs, Inc. director Patrick G. Enright received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and were awarded as compensation rather than purchased in the open market.
These options vest in full on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Enright continues to serve the company through that vesting date. Following this grant, he holds 22,000 stock options directly.
BioAge Labs, Inc. director Michael H. Davidson received a grant of stock options covering 22,000 shares of common stock. These options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. Following this grant, Davidson holds 22,000 stock options directly.
BioAge Labs, Inc. director Jean Pierre Garnier received a grant of stock options covering 22,000 shares of common stock at an exercise price of $15.48 per share. The options vest in full on the earlier of the next annual stockholder meeting or one year from the grant date, subject to continued service, and expire on June 9, 2036.
BioAge Labs, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected three Class II directors — Patrick Enright, James I. Healy, and Rekha Hemrajani — each to serve a three-year term expiring at the 2029 annual meeting.
Enright received 30,075,928 shares voted for and 1,184,271 withheld, Healy received 25,499,205 for and 5,760,994 withheld, and Hemrajani received 27,826,781 for and 3,433,418 withheld, with 5,327,405 broker non-votes for each nominee. Stockholders also ratified KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 36,561,171 shares for, 1,305 against, and 25,128 abstaining.